Company Description
Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States.
The company’s pipeline includes PEMGARDA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate, which is in preclinical studies for the prevention or treatment of COVID-19; and Adintrevimab that is in phase 2/3 clinical trials for the prevention and treatment of COVID-19.
It also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. The company has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies.
The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022.
Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
| Country | United States |
| Founded | 2020 |
| IPO Date | Aug 6, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 100 |
| CEO | William Duke |
Contact Details
Address: 1601 Trapelo Road, Suite 178 Waltham, Massachusetts 02451 United States | |
| Phone | 781 819 0080 |
| Website | invivyd.com |
Stock Details
| Ticker Symbol | IVVD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001832038 |
| CUSIP Number | 00534A102 |
| ISIN Number | US00534A1025 |
| Employer ID | 85-1403134 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| William E. Duke Jr., M.B.A. | Chief Financial Officer, Principal Accounting Officer and Principal Executive Officer |
| Julie Green M.B.A. | Chief Human Resources Officer and Head of Communications |
| Timothy Lee | Chief Commercial Officer |
| Dr. Robert D. Allen Ph.D. | Chief Scientific Officer |
| Scott Young | Senior Vice President of Investor Relations and Corporate Communications |
| Jill Andersen J.D. | Chief Legal Officer and Corporate Secretary |
| Dr. Mark A. Wingertzahn Ph.D. | Senior Vice President of Clinical Development and Medical Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 8, 2025 | SCHEDULE 13G | Filing |
| Aug 29, 2025 | SCHEDULE 13G | Filing |
| Aug 27, 2025 | SCHEDULE 13G | Filing |
| Aug 26, 2025 | SCHEDULE 13D/A | Filing |
| Aug 22, 2025 | 8-K | Current Report |
| Aug 22, 2025 | 424B5 | Filing |
| Aug 20, 2025 | FWP | Free Writing Prospectus |
| Aug 20, 2025 | 424B5 | Filing |
| Aug 18, 2025 | 144 | Filing |
| Aug 18, 2025 | 144 | Filing |